Details for New Drug Application (NDA): 203568
✉ Email this page to a colleague
The generic ingredient in KYNAMRO is mipomersen sodium. Additional details are available on the mipomersen sodium profile page.
Summary for 203568
Tradename: | KYNAMRO |
Applicant: | Kastle Theraps Llc |
Ingredient: | mipomersen sodium |
Patents: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 203568
Generic Entry Date for 203568*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 200MG/ML (200MG/ML) | ||||
Approval Date: | Jan 29, 2013 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 29, 2027 | Product Flag? | Substance Flag? | Y | Delist Request? |
Expired US Patents for NDA 203568
Complete Access Available with Subscription